Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153758 · ClinicalTrials.gov registry record · Phase 1
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT06153758 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 33 participants.
The verdict
NCT06153758, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.
Interventions
- DRUG Danuglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06153758
The ClinicalTrials.gov registry entry for NCT06153758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Danuglipron is the first listed.
NCT06153758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06153758 about?
NCT06153758 is a clinical study titled "Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults". The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.
What is the current status of trial NCT06153758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-11-27. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06153758?
The interventions under investigation include: Danuglipron (DRUG).
Who is sponsoring clinical trial NCT06153758?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.